Uniphar | Clinical merges with BMclinical

Feb 18, 2026 | News

Image Source: Bringing global capabilities together: Uniphar | Clinical’s facilities in Europe and the U.S. now operate as one unified clinical supply platform, strengthening end-to-end support for sponsors worldwide.
Written by: Contributor
On behalf of: Life Science Daily News

Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide.  

As part of Uniphar’s global platform supporting the full product lifecycle – from early clinical development through to commercialization and beyond – Uniphar | Clinical leverages scalable infrastructure and deep expertise to provide bespoke packaging, labeling, storage and distribution solutions, while BMclinical brings extensive experience in comparator sourcing and clinical trial supply.  

The combined Uniphar | Clinical offering will streamline clinical supply chains, minimize execution risk, and ensure continuity from study initiation through to completion, helping sponsors deliver therapies to patients faster. In addition, this broader offering enhances Uniphar’s ability to support partners across every stage of development, capitalizing on the scale and efficiency of a unified global sourcing model.  

“As global trials become more complex, sponsors increasingly value partners who can combine scale with specialist expertise,” said Dermot Ryan, Chief Operating Officer at Uniphar.
“By aligning BMclinical’s sourcing capabilities with Uniphar | Clinical’s integrated platform, we provide a comprehensive suite of clinical services based on agility and dependability that set a new standard for our partners and ultimately accelerate patient access to critical therapies.” 
 

Integrated services   

Building on Uniphar | Clinical’s and BMclinical’s combined expertise, the new partnership offers a comprehensive range of integrated services designed to support every stage of clinical trial supply, including: commercial drug supply capability including global sourcing of comparators; packaging and labeling services spanning both primary and secondary clinical packaging; global storage and distribution capabilities, including compliant facilities equipped with real-time temperature monitoring; and overage management solutions.   

With strategically located GMP- and GDP-compliant flagship facilities in Lelystad, the Netherlands, and Raleigh, North Carolina, alongside a distribution footprint spanning Europe, North America, APAC, and MENA, the partnership is positioned to deliver temperature-sensitive clinical materials reliably, wherever trials are underway.  

Shanelle Austin-Mehta, Director of Uniphar | Clinical said: 

“Bringing the expertise of Uniphar | Clinical and BMclinical together creates an unparalleled service offering to the pharmaceutical and biotech industry – one designed to anticipate challenges and provide the reliability sponsors need to keep studies on track.”  

For more information, visit https://unipharclinical.com/   

    References: None.

    Articles that may be of interest

    NHS England First in World to Offer Blenrep for Myeloma

    NHS England First in World to Offer Blenrep for Myeloma

    Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...

    read more
    Weekly News Roundup | 20 April 2026

    Weekly News Roundup | 20 April 2026

    Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...

    read more
    Weekly News Roundup | 13 April 2026

    Weekly News Roundup | 13 April 2026

    Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...

    read more

    Articles that may be of interest

    NHS England First in World to Offer Blenrep for Myeloma

    NHS England First in World to Offer Blenrep for Myeloma

    Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...

    read more
    Weekly News Roundup | 20 April 2026

    Weekly News Roundup | 20 April 2026

    Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...

    read more
    Weekly News Roundup | 13 April 2026

    Weekly News Roundup | 13 April 2026

    Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...

    read more